RU2007136616A - Композиция и способ для местного применения и чрескожного введения ботулинового токсина - Google Patents
Композиция и способ для местного применения и чрескожного введения ботулинового токсина Download PDFInfo
- Publication number
- RU2007136616A RU2007136616A RU2007136616/15A RU2007136616A RU2007136616A RU 2007136616 A RU2007136616 A RU 2007136616A RU 2007136616/15 A RU2007136616/15 A RU 2007136616/15A RU 2007136616 A RU2007136616 A RU 2007136616A RU 2007136616 A RU2007136616 A RU 2007136616A
- Authority
- RU
- Russia
- Prior art keywords
- composition according
- positively charged
- charged carrier
- skin surface
- agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Birds (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Wood Science & Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1. Состав, включающий: ! ботулинический токсин, ! положительно заряженный носитель и, ! по меньшей мере, одно вещество, выбранное из группы, состоящей из распределяющего агента, олигомерного мостикового соединения и полианионного мостикового соединения, ! при этом ботулинический токсин входит в состав нековалентного комплекса с положительно заряженным носителем. ! 2. Состав по п.1, отличающийся тем, что положительно заряженный носитель содержит также боковые группы. ! 3. Состав по п.1 или 2, отличающийся тем, что положительно заряженный носитель имеет молекулярный вес менее 21 000. ! 4. Состав по п.3, отличающийся тем, что положительно заряженный носитель представляет собой полилизин или PEI. ! 5. Состав по п.2, отличающийся тем, что боковые группы представляют собой защищенный олигоаргинин или домены TAT. ! 6. Состав по п.1, отличающийся тем, что он содержит дополнительно агент, модифицирующий вязкость. ! 7. Состав по п.6, отличающийся тем, что агент, модифицирующий вязкость, представляет собой гидроксипропилцеллюлозу или Cetaphil. ! 8. Набор для трансдермальной доставки ботулинического токсина, содержащий состав по п.1. ! 9. Способ обработки морщин, включающий нанесение на поверхность кожи пациента состава по п.1 и возможное последующее нанесение агента окклюзии. ! 10. Способ лечения гипергидроза, включающий нанесение на поверхность кожи пациента состава по п.1 и возможное последующее нанесение агента окклюзии. ! 11. Способ по п.9, отличающийся тем, что поверхность кожи выбрана из группы, состоящей из поверхности лица, лба, шеи, рук и ног. ! 12. Способ по п.10, отличающийся тем, что поверхность кожи выбрана из группы, состоящей из поверхности подмышечн
Claims (12)
1. Состав, включающий:
ботулинический токсин,
положительно заряженный носитель и,
по меньшей мере, одно вещество, выбранное из группы, состоящей из распределяющего агента, олигомерного мостикового соединения и полианионного мостикового соединения,
при этом ботулинический токсин входит в состав нековалентного комплекса с положительно заряженным носителем.
2. Состав по п.1, отличающийся тем, что положительно заряженный носитель содержит также боковые группы.
3. Состав по п.1 или 2, отличающийся тем, что положительно заряженный носитель имеет молекулярный вес менее 21 000.
4. Состав по п.3, отличающийся тем, что положительно заряженный носитель представляет собой полилизин или PEI.
5. Состав по п.2, отличающийся тем, что боковые группы представляют собой защищенный олигоаргинин или домены TAT.
6. Состав по п.1, отличающийся тем, что он содержит дополнительно агент, модифицирующий вязкость.
7. Состав по п.6, отличающийся тем, что агент, модифицирующий вязкость, представляет собой гидроксипропилцеллюлозу или Cetaphil.
8. Набор для трансдермальной доставки ботулинического токсина, содержащий состав по п.1.
9. Способ обработки морщин, включающий нанесение на поверхность кожи пациента состава по п.1 и возможное последующее нанесение агента окклюзии.
10. Способ лечения гипергидроза, включающий нанесение на поверхность кожи пациента состава по п.1 и возможное последующее нанесение агента окклюзии.
11. Способ по п.9, отличающийся тем, что поверхность кожи выбрана из группы, состоящей из поверхности лица, лба, шеи, рук и ног.
12. Способ по п.10, отличающийся тем, что поверхность кожи выбрана из группы, состоящей из поверхности подмышечной ямки, лба, спины, груди, ладоней, дорсальной части руки, тыльной части стопы или подошвы ноги.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65843405P | 2005-03-03 | 2005-03-03 | |
US60/658,434 | 2005-03-03 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2013114743/15A Division RU2013114743A (ru) | 2005-03-03 | 2013-04-02 | Композиции и способы для топического нанесения и трансдермальной доставки ботулинических токсинов |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2007136616A true RU2007136616A (ru) | 2009-04-10 |
Family
ID=36941888
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2007136616/15A RU2007136616A (ru) | 2005-03-03 | 2006-03-03 | Композиция и способ для местного применения и чрескожного введения ботулинового токсина |
RU2013114743/15A RU2013114743A (ru) | 2005-03-03 | 2013-04-02 | Композиции и способы для топического нанесения и трансдермальной доставки ботулинических токсинов |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2013114743/15A RU2013114743A (ru) | 2005-03-03 | 2013-04-02 | Композиции и способы для топического нанесения и трансдермальной доставки ботулинических токсинов |
Country Status (17)
Country | Link |
---|---|
US (4) | US9180081B2 (ru) |
EP (1) | EP1861112A4 (ru) |
JP (2) | JP2008531732A (ru) |
KR (2) | KR101453963B1 (ru) |
CN (3) | CN102499981B (ru) |
AU (1) | AU2006218431B2 (ru) |
BR (1) | BRPI0608249A2 (ru) |
CA (1) | CA2599017C (ru) |
CR (1) | CR9351A (ru) |
HK (1) | HK1119934A1 (ru) |
IL (2) | IL185299A (ru) |
MX (1) | MX2007010673A (ru) |
NO (1) | NO20074980L (ru) |
RU (2) | RU2007136616A (ru) |
SG (1) | SG160357A1 (ru) |
WO (1) | WO2006094263A2 (ru) |
ZA (1) | ZA200707352B (ru) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040220100A1 (en) * | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
WO2002007773A2 (en) * | 2000-07-21 | 2002-01-31 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
US7763663B2 (en) | 2001-12-19 | 2010-07-27 | University Of Massachusetts | Polysaccharide-containing block copolymer particles and uses thereof |
US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
BRPI0508410B8 (pt) | 2004-03-03 | 2021-05-25 | Revance Therapeutics Inc | composições e métodos para a aplicação tópica e liberação transdérmica de toxinas botulínicas |
AU2005251676B2 (en) * | 2004-03-03 | 2011-09-29 | Revance Therapeutics, Inc. | Compositions and methods for topical diagnostic and therapeutic transport |
US9180081B2 (en) * | 2005-03-03 | 2015-11-10 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
JP5401092B2 (ja) * | 2005-06-03 | 2014-01-29 | アクルックス・ディ・ディ・エス・プロプライエタリー・リミテッド | 経皮的薬物送達のための方法および組成物 |
BRPI0611134A2 (pt) | 2005-06-03 | 2010-08-17 | Acrux Dds Pty Ltd | método e composição para liberação transdérmica de fármaco |
JP5368793B2 (ja) | 2005-07-18 | 2013-12-18 | ユニバーシティ オブ マサチューセッツ ロウエル | ナノエマルジョンを製造および使用するための組成物および方法 |
US8168206B1 (en) * | 2005-10-06 | 2012-05-01 | Allergan, Inc. | Animal protein-free pharmaceutical compositions |
DK3295955T3 (da) | 2005-12-01 | 2021-07-05 | Univ Massachusetts Lowell | Botulinum nanoemulsioner |
US9486408B2 (en) | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
SG179457A1 (en) | 2006-12-01 | 2012-04-27 | Anterios Inc | Peptide nanoparticles and uses therefor |
KR20090106493A (ko) | 2006-12-01 | 2009-10-09 | 안테리오스, 인코퍼레이티드 | 양쪽성 엔티티 나노입자 |
NZ598159A (en) * | 2006-12-29 | 2013-08-30 | Revance Therapeutics Inc | Transport molecules using reverse sequence hiv-tat polypeptides |
BRPI0720730A2 (pt) * | 2006-12-29 | 2014-04-08 | Revance Therapeutics Inc | Composições e métodos de aplicação tópica e liberação transdérmica de toxinas botulínicas estabilizadas com fragmentos de polipeptídeo derivados de hiv-tat. |
CN103961315A (zh) | 2007-05-31 | 2014-08-06 | 安特里奥公司 | 核酸纳米粒子和其用途 |
SI2178549T1 (sl) | 2007-07-26 | 2017-08-31 | Revance Therapeutics, Inc. | Protimikrobni peptid in pripravki iz njega |
US9107815B2 (en) | 2008-02-22 | 2015-08-18 | Allergan, Inc. | Sustained release poloxamer containing pharmaceutical compositions |
KR101609894B1 (ko) | 2008-03-14 | 2016-04-08 | 알러간, 인코포레이티드 | 면역-기반 보툴리눔 독소 세로타입 a 활성 검정 |
CN105147608B (zh) * | 2008-06-26 | 2019-12-10 | 安特里奥公司 | 真皮递送 |
DK3332805T3 (da) | 2008-12-31 | 2022-05-16 | Revance Therapeutics Inc | Injicerbare botulinumtoksinformuleringer |
US8492109B2 (en) | 2009-01-20 | 2013-07-23 | Trustees Of Tufts College | Methods for the delivery of toxins or enzymatically active portions thereof |
DK2413947T3 (da) * | 2009-04-01 | 2020-06-02 | Revance Therapeutics Inc | Fremgangsmåder og sammensætninger til behandling af hudtilstande forbundet med vaskulær hyperreaktivitet |
KR101975051B1 (ko) * | 2009-06-25 | 2019-05-03 | 레반스 테라퓨틱스, 아이엔씨. | 알부민불포함 보툴리눔 독소 제제 |
US8147848B2 (en) | 2009-08-26 | 2012-04-03 | Allergan, Inc. | Method for treating premature ejaculation with a botulinum neurotoxin |
AU2010313529A1 (en) * | 2009-10-30 | 2012-04-12 | Duoject Medical Systems, Inc. | Device and method for topical application of therapeutics or cosmetic compositions |
US8454975B1 (en) * | 2010-01-11 | 2013-06-04 | Elizabeth VanderVeer | Method for enhancing skin appearance |
DK2661276T3 (en) * | 2011-01-07 | 2017-10-02 | Revance Therapeutics Inc | TOPICAL COMPOSITION INCLUDING BOTULINUM TOXIN AND A COLOR |
AU2013234988A1 (en) * | 2012-03-22 | 2014-10-09 | Revance Therapeutics, Inc. | Method of treatment of wrinkles using topical chemodenervating agents |
MX370929B (es) | 2012-10-28 | 2020-01-08 | Revance Therapeutics Inc | Composiciones y usos de las mismas para el tratamiento seguro de la rinitis. |
CN103083651A (zh) * | 2013-01-22 | 2013-05-08 | 南京中医药大学 | 用于外用制剂的穿膜肽介导的肉毒毒素的组合物及其制备方法和应用 |
GB201312317D0 (en) | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
SG11201704699YA (en) * | 2014-12-08 | 2017-07-28 | JJSK R&D Pte Ltd | Carrier molecule compositions and related methods |
WO2016110662A1 (en) * | 2015-01-09 | 2016-07-14 | Ipsen Bioinnovation Limited | Cationic neurotoxins |
AR103244A1 (es) * | 2015-02-03 | 2017-04-26 | Merz Pharma Gmbh & Co Kgaa | Recipiente precargado con toxina botulínica |
CA3036095A1 (en) | 2016-09-13 | 2018-03-22 | Allergan, Inc. | Stabilized non-protein clostridial toxin compositions |
KR102487144B1 (ko) | 2016-11-21 | 2023-01-12 | 에이리온 테라퓨틱스, 인코포레이티드 | 큰 물질의 경피 전달 |
EP3641746A4 (en) | 2017-06-19 | 2021-03-17 | President And Fellows Of Harvard College | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIAL INFECTION |
US10232009B1 (en) * | 2017-09-29 | 2019-03-19 | Pro Sunfun Biotech Research And Development Co., Ltd. | Peptide for promoting wound healing, its composition and method of using the same |
KR20190038292A (ko) | 2017-09-29 | 2019-04-08 | 한국프라임제약주식회사 | 효능 지속시간이 연장된 보툴리눔 독소 조성물 |
WO2019090257A1 (en) * | 2017-11-03 | 2019-05-09 | Revance Therapeutics, Inc. | Botulinum toxin formulations and methods of use thereof in plantar fasciitis with extended duration of effect |
AU2018378465A1 (en) * | 2017-12-04 | 2020-07-09 | Revance Therapeutics, Inc. | Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration |
WO2019126502A1 (en) | 2017-12-20 | 2019-06-27 | Allergan, Inc. | Botulinum toxin cell binding domain polypeptides and methods of use for skin rejuvenation |
CN112584856A (zh) * | 2018-06-13 | 2021-03-30 | 德玛塔疗法有限责任公司 | 用于治疗皮肤疾患的组合物 |
BR112023010936A2 (pt) * | 2020-12-02 | 2023-10-03 | Univ Johns Hopkins | Composições de nanopartículas poliméricas para encapsulamento e liberação sustentada de neuromoduladores |
CA3206148A1 (en) | 2021-01-24 | 2022-07-28 | Michael David FORREST | Therapeutic modifiers of the reverse mode of atp synthase |
Family Cites Families (176)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4078060A (en) * | 1976-05-10 | 1978-03-07 | Richardson-Merrell Inc. | Method of inducing an estrogenic response |
US4434228A (en) * | 1982-04-20 | 1984-02-28 | Genex Corporation | Immobilization of biological materials in condensed polyalkyleneimine polymers |
US4816568A (en) | 1986-05-16 | 1989-03-28 | International Minerals & Chemical Corp. | Stabilization of growth hormones |
JPS63287730A (ja) | 1987-05-20 | 1988-11-24 | Nippon Shokubai Kagaku Kogyo Co Ltd | 経皮吸収促進剤およびこれを含有してなる皮膚外用剤 |
US5252713A (en) * | 1988-09-23 | 1993-10-12 | Neorx Corporation | Polymeric carriers for non-covalent drug conjugation |
US5420105A (en) * | 1988-09-23 | 1995-05-30 | Gustavson; Linda M. | Polymeric carriers for non-covalent drug conjugation |
US5744166A (en) * | 1989-02-25 | 1998-04-28 | Danbiosyst Uk Limited | Drug delivery compositions |
US6126945A (en) * | 1989-10-03 | 2000-10-03 | Pharmacia Ab | Tumor killing effects of enterotoxins, superantigens, and related compounds |
US5747641A (en) | 1989-12-21 | 1998-05-05 | Biogen Inc | Tat-derived transport polypeptide conjugates |
US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
US5629020A (en) | 1994-04-22 | 1997-05-13 | Emisphere Technologies, Inc. | Modified amino acids for drug delivery |
DE69123754T2 (de) | 1990-10-24 | 1997-04-03 | Allelix Biopharma | Peptidische hemmer der hiv-replikation |
GB9120306D0 (en) * | 1991-09-24 | 1991-11-06 | Graham Herbert K | Method and compositions for the treatment of cerebral palsy |
US5607691A (en) | 1992-06-12 | 1997-03-04 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
CA2135642C (en) | 1992-08-21 | 1999-12-14 | James G. Barsoum | Tat-derived transport polypeptides |
US5260082A (en) | 1992-09-16 | 1993-11-09 | Kraft General Foods, Inc. | Baked goods, doughs or batters, dry mixes and methods for producing thereof |
US5877278A (en) * | 1992-09-24 | 1999-03-02 | Chiron Corporation | Synthesis of N-substituted oligomers |
US5709861A (en) * | 1993-04-22 | 1998-01-20 | Emisphere Technologies, Inc. | Compositions for the delivery of antigens |
DE69433394T3 (de) | 1993-12-28 | 2010-08-12 | Allergan, Inc., Irvine | Botulinustoxine zur Modulation cholinergisch-kontrollierter Sekretionen |
US6974578B1 (en) * | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
US6986893B2 (en) * | 1993-12-28 | 2006-01-17 | Allergan, Inc. | Method for treating a mucus secretion |
US5766605A (en) | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
DK1086702T3 (da) * | 1994-05-09 | 2005-05-23 | William J Binder | Præsynaptiske neurotoksiner til behandling af migrænehovedpine |
NO180167C (no) * | 1994-09-08 | 1997-02-26 | Photocure As | Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol |
US6232295B1 (en) | 1994-10-12 | 2001-05-15 | Jon Faiz Kayyem | Cell-specific contrast agent and gene delivery vehicles |
US5756468A (en) * | 1994-10-13 | 1998-05-26 | Wisconsin Alumni Research Foundation | Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation |
US5512547A (en) * | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
GB9508204D0 (en) * | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
GB9600272D0 (en) | 1996-01-06 | 1996-03-06 | Univ Nottingham | Polymers |
JP2000509394A (ja) | 1996-05-01 | 2000-07-25 | アンティバイラルズ インコーポレイテッド | 細胞膜を横切って物質を輸送するためのポリペプチド結合体 |
US6444209B1 (en) * | 1996-10-28 | 2002-09-03 | Wisconsin Alumni Research Foundation | Hybrid botulinal neurotoxins |
GB9623051D0 (en) | 1996-11-06 | 1997-01-08 | Schacht Etienne H | Delivery of DNA to target cells in biological systems |
FR2755976B1 (fr) | 1996-11-15 | 1999-01-15 | Idm Immuno Designed Molecules | Nouveaux complexes d'acides nucleiques et de polymere substitue par des residus entrainant la destabilisation des membranes cellulaires |
US6228161B1 (en) | 1996-12-30 | 2001-05-08 | Minerals Technologies Inc. | Use of calcium carbonate in an acidic aqueous media |
FR2759298B1 (fr) | 1997-02-10 | 1999-04-09 | Rhone Poulenc Rorer Sa | Formulation de particules agent(s) de transfection cationique(s)/acides nucleiques stabilisees |
PL337033A1 (en) * | 1997-05-21 | 2000-07-31 | Univ Leland Stanford Junior | Composition for and methods of enhancing transport through permeable biological membranes |
US7150881B2 (en) | 1997-06-26 | 2006-12-19 | Mylan Technologies, Inc. | Adhesive mixture for transdermal delivery of highly plasticizing drugs |
AU1387299A (en) | 1997-11-12 | 1999-05-31 | Valentis, Inc. | Expression plasmids for multiepitope nucleic acid-based vaccines |
US5985434A (en) * | 1997-11-25 | 1999-11-16 | Kimberly-Clark Worldwide, Inc. | Absorbent foam |
WO1999029721A1 (en) | 1997-12-10 | 1999-06-17 | Washington University | Anti-pathogen system and methods of use thereof |
WO1999042091A2 (en) * | 1998-02-19 | 1999-08-26 | Massachusetts Institute Of Technology | Use of polycations as endosomolytic agents |
US6011646A (en) | 1998-02-20 | 2000-01-04 | The Regents Of The Unviersity Of California | Method to adjust multilayer film stress induced deformation of optics |
EP1061951B1 (en) | 1998-02-25 | 2003-08-27 | THE GOVERNMENT OF THE UNITED STATES, as represented by THE SECRETARY OF THE ARMY | Use of skin penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response induced by adp-ribosylating exotoxin |
AU749475B2 (en) | 1998-04-27 | 2002-06-27 | Astellas Pharma Inc. | Medicinal compositions |
US6261679B1 (en) | 1998-05-22 | 2001-07-17 | Kimberly-Clark Worldwide, Inc. | Fibrous absorbent material and methods of making the same |
WO2000002950A1 (en) * | 1998-07-13 | 2000-01-20 | Expression Genetics, Inc. | Polyester analogue of poly-l-lysine as a soluble, biodegradable gene delivery carrier |
US6280937B1 (en) * | 1998-08-14 | 2001-08-28 | Rigel Pharmaceuticals, Inc. | Shuttle vectors |
TW574036B (en) | 1998-09-11 | 2004-02-01 | Elan Pharm Inc | Stable liquid compositions of botulinum toxin |
US6958147B1 (en) * | 1998-10-26 | 2005-10-25 | Licentia Ltd | Use of VEGF-C to prevent restenosis |
CN1324246A (zh) * | 1998-10-27 | 2001-11-28 | 梅约医学教育与研究基金会 | 增加伤口愈合的方法 |
WO2000032764A1 (en) | 1998-12-02 | 2000-06-08 | I.D.M. Immuno-Designed Molecules | New oligomeric conjugates liable to transfer biological molecules into cells |
WO2000034308A2 (en) | 1998-12-10 | 2000-06-15 | Washington University | Protein transduction system and methods of use thereof |
US6627632B2 (en) * | 1998-12-14 | 2003-09-30 | Cellegy Pharmaceuticals, Inc. | Compositions and methods for the treatment of anorectal disorders |
JP2002533379A (ja) | 1998-12-23 | 2002-10-08 | イデア アクチェンゲゼルシャフト | 生体内における局所的に非侵襲性である用途のための改善された製剤 |
US7056656B1 (en) * | 1999-01-25 | 2006-06-06 | University Of Medicine And Dentistry Of New Jersey | Tat-derived oligourea and its method of production and use in high affinity and specific binding HIV-1 TAR RNA |
ES2160485B1 (es) | 1999-04-23 | 2002-05-16 | Lipotec Sa | Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen. |
US7442764B2 (en) * | 1999-06-07 | 2008-10-28 | Mirns Bio Corporation | Reversible modification of amine-containing compounds |
DE19925739A1 (de) | 1999-06-07 | 2000-12-21 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum mit einem Botulinum-Neurotoxin |
US20030236214A1 (en) | 1999-06-09 | 2003-12-25 | Wolff Jon A. | Charge reversal of polyion complexes and treatment of peripheral occlusive disease |
US7008924B1 (en) * | 1999-07-21 | 2006-03-07 | Amgen, Inc. | VGF fusion polypeptides |
US7229961B2 (en) | 1999-08-24 | 2007-06-12 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into ocular tissues |
US6730293B1 (en) * | 1999-08-24 | 2004-05-04 | Cellgate, Inc. | Compositions and methods for treating inflammatory diseases of the skin |
US6593292B1 (en) | 1999-08-24 | 2003-07-15 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
US6669951B2 (en) | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
US20030104622A1 (en) * | 1999-09-01 | 2003-06-05 | Robbins Paul D. | Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses |
US6544548B1 (en) * | 1999-09-13 | 2003-04-08 | Keraplast Technologies, Ltd. | Keratin-based powders and hydrogel for pharmaceutical applications |
US6458763B1 (en) * | 1999-09-17 | 2002-10-01 | Depuy Orthopeadics | Bone sialoprotein-based compositions for enhancing connective tissue repair |
US6773928B1 (en) * | 1999-09-22 | 2004-08-10 | The United States Of America As Represented By The Secretary Of The Army | Compositions and methods for enhancing bioassay performance |
US6610820B1 (en) * | 1999-10-12 | 2003-08-26 | University Of Lausanne | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
US6511676B1 (en) * | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
US6844324B1 (en) * | 1999-11-12 | 2005-01-18 | Massachusetts Institute Of Technology | Modular peptide mediated intracellular delivery system and uses therefore |
US7070807B2 (en) | 1999-12-29 | 2006-07-04 | Mixson A James | Branched histidine copolymers and methods for using same |
US20040109871A1 (en) * | 2000-01-06 | 2004-06-10 | Pascual David W. | M cell directed vaccines |
DE60110372T2 (de) * | 2000-02-08 | 2006-01-19 | Allergan, Inc., Irvine | Pharmazeutische zusammensetzungen mit botulinumtoxin |
US20030118598A1 (en) | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
US7780967B2 (en) * | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
US20020009491A1 (en) | 2000-02-14 | 2002-01-24 | Rothbard Jonathan B. | Compositions and methods for enhancing drug delivery across biological membranes and tissues |
AT411041B (de) * | 2000-05-18 | 2003-09-25 | Josef Lindenberg | Verfahren zur herstellung von glasfliesen, glasbordüren, glasdekorpaneelen oder dgl. |
US6670322B2 (en) * | 2000-06-01 | 2003-12-30 | Wisconsin Alumni Research Foundation | Method of targeting pharmaceuticals to motor neurons |
US20040033241A1 (en) | 2000-06-02 | 2004-02-19 | Allergan, Inc. | Controlled release botulinum toxin system |
US6306423B1 (en) | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
US6306403B1 (en) * | 2000-06-14 | 2001-10-23 | Allergan Sales, Inc. | Method for treating parkinson's disease with a botulinum toxin |
US20030215412A1 (en) | 2000-07-21 | 2003-11-20 | Essentia Biosystems, Inc. | Induction of hair growth with vascular endothelial growth factor |
US20040220100A1 (en) * | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
WO2002007773A2 (en) * | 2000-07-21 | 2002-01-31 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
US7491799B2 (en) | 2000-07-21 | 2009-02-17 | Allergan, Inc. | Modified botulinum neurotoxins |
US20030219462A1 (en) | 2000-07-21 | 2003-11-27 | Allergan Sales, Inc | Clostridial neurotoxin compositions and modified clostridial neurotoxins |
US6903187B1 (en) * | 2000-07-21 | 2005-06-07 | Allergan, Inc. | Leucine-based motif and clostridial neurotoxins |
JP2002072267A (ja) * | 2000-08-25 | 2002-03-12 | National Institute For Materials Science | 光機能素子、該素子用単結晶基板、およびその使用方法 |
US6696038B1 (en) * | 2000-09-14 | 2004-02-24 | Expression Genetics, Inc. | Cationic lipopolymer as biocompatible gene delivery agent |
US6831059B2 (en) | 2000-10-20 | 2004-12-14 | Allergan, Inc. | Compositions and methods for treating gonadotrophin related illnesses |
US20020127247A1 (en) | 2000-11-17 | 2002-09-12 | Allergen Sales, Inc. | Modified clostridial neurotoxins with altered biological persistence |
US7255865B2 (en) * | 2000-12-05 | 2007-08-14 | Allergan, Inc. | Methods of administering botulinum toxin |
US20020086036A1 (en) * | 2000-12-05 | 2002-07-04 | Allergan Sales, Inc. | Methods for treating hyperhidrosis |
WO2002065986A2 (en) | 2001-02-16 | 2002-08-29 | Cellgate, Inc. | Transporters comprising spaced arginine moieties |
WO2002072608A2 (en) * | 2001-03-09 | 2002-09-19 | University Of Chicago | POLYMERIC IMMUNOGLOBULIN FUSION PROTEINS THAT TARGET LOW-AFFINITY FCηRECEPTORS |
CA2367636C (en) * | 2001-04-12 | 2010-05-04 | Lisa Mckerracher | Fusion proteins |
US7226605B2 (en) | 2001-07-27 | 2007-06-05 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Botulinum toxin in the treatment or prevention of acne |
DE10146647A1 (de) * | 2001-09-21 | 2003-04-24 | Marc Heckmann | Arzneimittel zur Prophylaxe und Therapie von Bromhidrosis |
JP2005508990A (ja) * | 2001-11-07 | 2005-04-07 | ファルマシア・コーポレーション | 真核細胞におけるポリアミドの取込みおよび核蓄積を促進する方法 |
US7060498B1 (en) * | 2001-11-28 | 2006-06-13 | Genta Salus Llc | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
AU2002359679B2 (en) | 2001-12-11 | 2009-01-08 | Cellgate, Inc. | Guanidinium transport reagents and conjugates |
US20030113349A1 (en) * | 2001-12-18 | 2003-06-19 | Coleman William P. | Topically applied clostridium botulinum toxin compositions and treatment methods |
AU2002360712A1 (en) * | 2001-12-21 | 2003-07-30 | The Trustees Of Columbia University In The City Of New York | C3 exoenzyme-coated stents and uses thereof for treating and preventing restenosis |
US20030147958A1 (en) * | 2002-01-29 | 2003-08-07 | Cheol-Hee Ahn | Biodegradable multi-block copolymers of poly(amino acid)s and poly(ethylene glycol) for the delivery of bioactive agents |
WO2003072049A2 (en) | 2002-02-21 | 2003-09-04 | Essentia Biosystems, Inc. | Induction of hair growth with vascular endothelial growth factor |
SG165155A1 (en) * | 2002-02-26 | 2010-10-28 | Maxygen Inc | Novel flavivirus antigens |
WO2003072143A1 (en) | 2002-02-27 | 2003-09-04 | Pharmain, Ltd. | Compositions for delivery of therapeutics and other materials, and methods of making and using the same |
US6688311B2 (en) * | 2002-03-14 | 2004-02-10 | Allergan, Inc. | Method for determining effect of a clostridial toxin upon a muscle |
US20030215395A1 (en) * | 2002-05-14 | 2003-11-20 | Lei Yu | Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier |
CN1383811A (zh) * | 2002-05-16 | 2002-12-11 | 卢伟成 | 一种除皱化妆品及其制作工艺 |
US7459164B2 (en) * | 2002-05-28 | 2008-12-02 | Botulinum Toxin Research Associates, Inc. | Composition for therapeutic and cosmetic botulinum toxin |
WO2003101484A1 (en) * | 2002-05-31 | 2003-12-11 | Thomas Jefferson University | Compositions and methods for transepithelial molecular transport |
US20040009180A1 (en) * | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
US20040242518A1 (en) * | 2002-09-28 | 2004-12-02 | Massachusetts Institute Of Technology | Influenza therapeutic |
US9265725B2 (en) * | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US7071167B2 (en) * | 2002-11-13 | 2006-07-04 | L'oreal | Use of a combination of components with an inhibitory synergistic effect on calcium channels to prevent or treat wrinkles and fine lines |
WO2004050068A1 (en) * | 2002-11-29 | 2004-06-17 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
US6866856B2 (en) * | 2002-12-31 | 2005-03-15 | Avon Products, Inc. | Compositions and delivery methods for the treatment of wrinkles, fine lines and hyperhidrosis |
US7482016B2 (en) | 2003-03-19 | 2009-01-27 | The J. David Gladstone Institutes | Immunogenic compositions comprising HIV-1 acetylated Tat polypeptides |
US20040247623A1 (en) * | 2003-03-24 | 2004-12-09 | Roger Cady | Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin |
US20040192754A1 (en) | 2003-03-24 | 2004-09-30 | Shapira Nathan Andrew | Methods for treating idiopathic hyperhidrosis and associated conditions |
WO2005030119A2 (en) * | 2003-04-11 | 2005-04-07 | Allergan, Inc. | Botulinum toxin a peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy |
WO2005002597A1 (en) * | 2003-07-02 | 2005-01-13 | Polycord, Inc. | Method for delivering polymerized therapeutic agent compositions and compositions thereof |
WO2005007819A2 (en) * | 2003-07-09 | 2005-01-27 | Wisconsin Alumni Research Foundation | Charge-dynamic polymers and delivery of anionic compounds |
DE10333317A1 (de) | 2003-07-22 | 2005-02-17 | Biotecon Therapeutics Gmbh | Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA) |
US8871224B2 (en) * | 2003-12-09 | 2014-10-28 | Allergan, Inc. | Botulinum toxin therapy for skin disorders |
BRPI0508410B8 (pt) * | 2004-03-03 | 2021-05-25 | Revance Therapeutics Inc | composições e métodos para a aplicação tópica e liberação transdérmica de toxinas botulínicas |
AU2005251676B2 (en) * | 2004-03-03 | 2011-09-29 | Revance Therapeutics, Inc. | Compositions and methods for topical diagnostic and therapeutic transport |
US9211248B2 (en) * | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
US7691381B2 (en) * | 2004-04-15 | 2010-04-06 | Allergan, Inc. | Stabilized biodegradable neurotoxin implants |
US20060040882A1 (en) * | 2004-05-04 | 2006-02-23 | Lishan Chen | Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells |
GB2416122A (en) | 2004-07-12 | 2006-01-18 | Ipsen Ltd | Botulinum neurotoxin composition |
KR100852822B1 (ko) * | 2004-07-26 | 2008-08-18 | 메르츠 파마 게엠베하 운트 코. 카가아 | 보툴리눔 신경독소를 포함하는 치료 조성물 |
US20060024331A1 (en) * | 2004-08-02 | 2006-02-02 | Ester Fernandez-Salas | Toxin compounds with enhanced membrane translocation characteristics |
JP2006067889A (ja) * | 2004-09-01 | 2006-03-16 | Japan Science & Technology Agency | Peoと二本鎖核酸のコンジュゲート |
US9180081B2 (en) | 2005-03-03 | 2015-11-10 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
WO2006094193A2 (en) * | 2005-03-03 | 2006-09-08 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of an oligopeptide |
JP2008532522A (ja) * | 2005-03-08 | 2008-08-21 | モレキュラー プローブス, インコーポレイテッド | ナノ構造を用いた細胞膜電位差のモニターおよび操作 |
DK2311972T3 (en) * | 2005-05-11 | 2015-04-27 | Eth Zuerich | Recombinant N-glycosylated proteins from prokaryotic cells |
DE102005039189B4 (de) | 2005-08-18 | 2010-09-09 | Siemens Ag | Bildauswertungsverfahren für zweidimensionale Projektionsbilder und hiermit korrespondierende Gegenstände |
US8137677B2 (en) * | 2005-10-06 | 2012-03-20 | Allergan, Inc. | Non-protein stabilized clostridial toxin pharmaceutical compositions |
US8168206B1 (en) * | 2005-10-06 | 2012-05-01 | Allergan, Inc. | Animal protein-free pharmaceutical compositions |
US8518414B2 (en) * | 2005-11-17 | 2013-08-27 | Revance Therapeutics, Inc. | Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins |
US9486408B2 (en) * | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
US20100021502A1 (en) | 2006-12-28 | 2010-01-28 | Waugh Jacob M | Compositions and Methods of Topical Application and Transdermal Delivery of Botulinum Toxins Stabililzed with Polypeptide Fragments Derived from HIV-TAT |
BRPI0720730A2 (pt) * | 2006-12-29 | 2014-04-08 | Revance Therapeutics Inc | Composições e métodos de aplicação tópica e liberação transdérmica de toxinas botulínicas estabilizadas com fragmentos de polipeptídeo derivados de hiv-tat. |
NZ598159A (en) * | 2006-12-29 | 2013-08-30 | Revance Therapeutics Inc | Transport molecules using reverse sequence hiv-tat polypeptides |
KR20100123730A (ko) * | 2008-02-20 | 2010-11-24 | 글리코박신 아게 | 원핵생물 세포로부터의 n-당화된 재조합 단백질로부터 제조된 바이오컨쥬게이트 |
US20170361130A9 (en) * | 2008-05-23 | 2017-12-21 | Pankaj Modi | Stabilized and solubilized drug formulation for topical application and transdermal efficacy for cosmetic improvement and methods of formulation |
US20100028385A1 (en) * | 2008-08-04 | 2010-02-04 | Allergan, Inc. | Treatment of excess cerumen secretion |
US8218414B2 (en) * | 2008-09-29 | 2012-07-10 | Panasonic Corporation | Information recording medium, recording method, and reproducing method |
JP5836128B2 (ja) * | 2008-12-31 | 2015-12-24 | ルバンス セラピュティックス インク.Revance Therapeutics,Inc. | 色素過剰を治療するための組成物及び方法 |
DK3332805T3 (da) * | 2008-12-31 | 2022-05-16 | Revance Therapeutics Inc | Injicerbare botulinumtoksinformuleringer |
DK2413947T3 (da) * | 2009-04-01 | 2020-06-02 | Revance Therapeutics Inc | Fremgangsmåder og sammensætninger til behandling af hudtilstande forbundet med vaskulær hyperreaktivitet |
KR101975051B1 (ko) * | 2009-06-25 | 2019-05-03 | 레반스 테라퓨틱스, 아이엔씨. | 알부민불포함 보툴리눔 독소 제제 |
US9504664B2 (en) * | 2010-10-29 | 2016-11-29 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US9737500B2 (en) * | 2010-10-29 | 2017-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
DK2661276T3 (en) * | 2011-01-07 | 2017-10-02 | Revance Therapeutics Inc | TOPICAL COMPOSITION INCLUDING BOTULINUM TOXIN AND A COLOR |
US8697090B2 (en) * | 2011-05-05 | 2014-04-15 | Allergan, Inc. | Method of treating persistent genital arousal disorder with a neurotoxin |
US8586020B2 (en) * | 2011-06-30 | 2013-11-19 | Korea Institute Of Science And Technology | Poly(organophosphazene) composition for biomaterials |
EP2755636A1 (en) * | 2011-09-16 | 2014-07-23 | The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Healthcare System | Amphiphilic cationic polymers for the delivery of therapeutic agents |
LT2791160T (lt) * | 2011-12-16 | 2022-06-10 | Modernatx, Inc. | Modifikuotos mrnr sudėtys |
EP2806793A4 (en) * | 2012-01-27 | 2016-05-25 | Revance Therapeutics Inc | EVALUATION METHODS AND SCALES FOR MEASURING WRINKLE GRAVITY |
AU2013234988A1 (en) * | 2012-03-22 | 2014-10-09 | Revance Therapeutics, Inc. | Method of treatment of wrinkles using topical chemodenervating agents |
US9541558B2 (en) * | 2012-09-05 | 2017-01-10 | California Institute Of Technology | Cysteine hydrazide nicotinamide for glycomics and glycoproteomics uses |
MX370929B (es) * | 2012-10-28 | 2020-01-08 | Revance Therapeutics Inc | Composiciones y usos de las mismas para el tratamiento seguro de la rinitis. |
US20150259283A1 (en) * | 2014-03-13 | 2015-09-17 | Brickell Biotech, Inc. | Formulation for soft anticholinergic analogs |
AU2015252947B2 (en) * | 2014-05-01 | 2020-07-09 | Anterios, Inc. | Demonstrable efficacy across or within patient populations |
RU2694820C9 (ru) * | 2014-12-23 | 2019-08-12 | Мерц Фарма Гмбх Унд Ко. Кгаа | Контейнер, предварительно заполненный ботулиновым токсином |
AR103244A1 (es) * | 2015-02-03 | 2017-04-26 | Merz Pharma Gmbh & Co Kgaa | Recipiente precargado con toxina botulínica |
DK3368071T3 (da) * | 2015-10-29 | 2022-05-02 | Revance Therapeutics Inc | Injicerbare botulinumtoksinformuleringer og fremgangsmåder til anvendelse deraf med langvarig terapeutisk eller kosmetisk virkning |
CA3020400A1 (en) * | 2016-04-12 | 2017-10-19 | Illustris Pharmaceuticals, Inc. | Compositions for topical application of compounds |
SG11202003229RA (en) * | 2017-10-11 | 2020-05-28 | Illustris Pharmaceuticals Inc | Methods and compositions for topical delivery |
EP4360690A2 (en) * | 2018-08-15 | 2024-05-01 | Allergan, Inc. | Microneedle array with active ingredient |
-
2006
- 2006-03-03 US US11/367,642 patent/US9180081B2/en active Active
- 2006-03-03 MX MX2007010673A patent/MX2007010673A/es active IP Right Grant
- 2006-03-03 RU RU2007136616/15A patent/RU2007136616A/ru not_active Application Discontinuation
- 2006-03-03 EP EP06748293A patent/EP1861112A4/en not_active Withdrawn
- 2006-03-03 WO PCT/US2006/007830 patent/WO2006094263A2/en active Application Filing
- 2006-03-03 BR BRPI0608249-1A patent/BRPI0608249A2/pt not_active IP Right Cessation
- 2006-03-03 KR KR1020147005118A patent/KR101453963B1/ko active IP Right Grant
- 2006-03-03 SG SG201001501-4A patent/SG160357A1/en unknown
- 2006-03-03 ZA ZA200707352A patent/ZA200707352B/xx unknown
- 2006-03-03 US US11/816,602 patent/US9314416B2/en active Active
- 2006-03-03 KR KR1020077022413A patent/KR20070110402A/ko active IP Right Grant
- 2006-03-03 CN CN201110324571.7A patent/CN102499981B/zh active Active
- 2006-03-03 CA CA2599017A patent/CA2599017C/en active Active
- 2006-03-03 CN CN201610412863.9A patent/CN106039294A/zh active Pending
- 2006-03-03 AU AU2006218431A patent/AU2006218431B2/en active Active
- 2006-03-03 JP JP2007558312A patent/JP2008531732A/ja active Pending
- 2006-03-03 CN CN2006800148394A patent/CN101171018B/zh active Active
-
2007
- 2007-08-15 IL IL185299A patent/IL185299A/en active IP Right Grant
- 2007-08-28 CR CR9351A patent/CR9351A/es not_active Application Discontinuation
- 2007-10-03 NO NO20074980A patent/NO20074980L/no not_active Application Discontinuation
-
2008
- 2008-10-30 HK HK08111947.3A patent/HK1119934A1/xx unknown
-
2012
- 2012-10-04 JP JP2012222288A patent/JP5883371B2/ja not_active Expired - Fee Related
-
2013
- 2013-04-02 RU RU2013114743/15A patent/RU2013114743A/ru not_active Application Discontinuation
- 2013-05-28 IL IL226612A patent/IL226612B/en not_active IP Right Cessation
-
2015
- 2015-11-09 US US14/935,886 patent/US10080786B2/en active Active
-
2018
- 2018-09-24 US US16/140,288 patent/US10744078B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2007136616A (ru) | Композиция и способ для местного применения и чрескожного введения ботулинового токсина | |
O’Halloran et al. | Adipose-derived stem cells in novel approaches to breast reconstruction: their suitability for tissue engineering and oncological safety | |
JP2019194251A5 (ru) | ||
JP2008531732A5 (ru) | ||
US20170157020A1 (en) | Method of treatment of wrinkles using topical chemodenervating agents | |
MX2007010674A (es) | Composiciones y metodos para la aplicacion topica y el suministro transdermico de un oligopeptido. | |
AR042545A1 (es) | Agentes ligantes que inhiben la miostatina | |
US20210189326A1 (en) | Methods and kits for topical application, removal, and inactivation of therapeutic or cosmetic toxin compositions | |
WO2010128672A1 (ja) | 遺伝子組み換えゼラチンを含む血管新生誘導剤 | |
JP2015514074A5 (ru) | ||
ES2732317T3 (es) | Material de relleno dermocosmético y usos del mismo para fines estéticos | |
WO2010147109A1 (ja) | 遺伝子組み換えゼラチン及び塩基性線維芽細胞増殖因子を含む血管新生誘導剤 | |
CN105343926A (zh) | 一种含有纳米二氧化硅的疤痕贴及其制备方法 | |
KR101933685B1 (ko) | 약물이 코팅된 마이크로 니들 및 이의 제조방법 | |
CN108697592A (zh) | 硅氧烷组合物 | |
JP2013544842A5 (ru) | ||
JP2013173794A5 (ru) | ||
JP2017014167A (ja) | 化粧用組成物 | |
Liu et al. | Influence of designer self‐assembling nanofiber scaffolds containing anti‐cancer peptide motif on hepatoma carcinoma cells | |
WO2017154708A1 (ja) | 毛髪処理方法及び毛髪処理剤セット | |
KR20130060594A (ko) | 환원당을 함유하는 헤어 트리트먼트 조성물 | |
Ying et al. | The transformation of multifunctional bio-patch to hydrogel on skin wounds for efficient scarless wound healing | |
Zhou et al. | An Immune‐Regulating Polysaccharide Hybrid Hydrogel with Mild Photothermal Effect and Anti‐Inflammatory for Accelerating Infected Wound Healing | |
TW201936160A (zh) | 優格狀化妝品組成物 | |
JP6709585B2 (ja) | 皮膚外用剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20110919 |
|
FZ9A | Application not withdrawn (correction of the notice of withdrawal) |
Effective date: 20111003 |